Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

F. Hoffmann-La Roche Ltd

The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAP In prostate cancer, PTEN protein loss is associated with faster disease progression and reduced benefit from current standard-of-care treatments1 The FDA approval reinforces Roche’s leadership in companion diagnostics and its ongoing commitment to expanding personalised healthcare to improve patient outcomes

Basel, 12 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the VENTANAⓇ PTEN (SP218) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive U.S. Food and Drug Administration (FDA) approval for determining PTEN protein loss, also known as PTEN deficiency, in tumours of patients with prostate adenocarcinoma. These patients may now be eligible for treatment with AstraZeneca’s targeted therapy TRUQAPⓇ (capivasertib).

“Prostate cancer is one of the leading cancer diagnoses for men in the United States,” said Matt Sause, CEO of Roche Diagnostics. “The FDA approval of our new companion diagnostic will provide clinicians with a vital tool to identify patients with PTEN loss and potentially provide new therapeutic options.”

PTEN is a tumour suppressor protein and loss of PTEN is commonly observed in a variety of cancers.2 Roche’s test enables patients with PTEN-deficient prostate cancer to potentially benefit from a combination treatment with TRUQAP. TRUQAP provides a new, first-line treatment option for patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC).3

Metastatic hormone-sensitive prostate cancer is an aggressive form of prostate cancer and treatments specifically targeting the PTEN protein loss biology were previously not available. The average length of survival after new, metastatic prostate cancer diagnosis is about 5 to 6 years.4 About 25% of patients with metastatic hormone-sensitive prostate cancer have PTEN-deficient tumors as evaluated by immunohistochemistry (IHC).1

Foundation Medicine, an independent affiliate of the Roche Group, is one laboratory using the VENTANA PTEN (SP218) RxDx Assay companion diagnostic kit to help healthcare providers identify patients with PTEN protein loss.

About the VENTANA PTEN (SP218) RxDx Assay The VENTANA PTEN (SP218) RxDx Assay is a qualitative immunohistochemical assay intended to be used in the assessment of PTEN protein in prostate adenocarcinoma. The OptiView DAB IHC Detection Kit is used for staining on a BenchMark ULTRA instrument. The assay is indicated as an aid in identifying patients with prostate adenocarcinoma who may be eligible for treatment with TRUQAP in combination with abiraterone acetate in accordance with the approved therapeutic product labeling.

Story Continues

The approval of the VENTANA PTEN (SP218) RxDx Assay is based on the results of the CAPItello-281 clinical study where it was used as the enrollment assay to identify patients whose tumours exhibited PTEN deficiency. The clinical cutoff for PTEN protein loss status is ≥ 90% of viable malignant cells with no specific cytoplasmic staining. PTEN protein loss status is based on the pathologist’s observation of an absence or presence of PTEN expression within prostate adenocarcinoma.5 Patients who received combination therapy with TRUQAP experienced a statistically significant and clinically meaningful reduction in disease progression.1

About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References [1] Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, Kwiatkowski M, Alvarez-Fernandez C, Jiang S, Sotelo M, Parslow D, Oliveira N, Kwon TG, Ye D, Boudewijns S, Danchaivijitr P, Rooney C, Gresty C, Yeste-Velasco M, Logan J, George DJ; CAPItello-281 Study Group. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026 Jan;37(1):53-68. [2] Luongo F, Colonna F, Calapà F, Vitale S, Fiori ME, De Maria R. PTEN Tumor-Suppressor: The Dam of Stemness in Cancer. Cancers (Basel). 2019 Jul 30;11(8):1076. doi: 10.3390/cancers11081076. PMID: 31366089; PMCID: PMC6721423. [3] AstraZeneca. Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial [Internet; published 2024 Nov 25; cited 2026 Feb 20]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-improved-rpfs-in-advanced-prostate-cancer.html. [4] MD Anderson Cancer Center. What to know about metastatic prostate cancer [Internet; published 2024 Dec 4; cited 2026 Feb 20]. The University of Texas. Available from: https://www.mdanderson.org/cancerwise/what-to-know-about-metastatic-prostate-cancer.h00-159703068.html#:~:text=What%20is%20the%20survival%20rate,doctor%20about%20your%20specific%20prognosis. [5] VENTANA PTEN (SP218) RxDx Assay Method Sheet (D206480 Rev 1), 2025.

Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD Phone: +41 79 407 72 58 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Irène Stephan Phone: +41 79 377 83 75

Attachment

Media Release PTEN FDA approval English

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Roper Technologies, Inc. ROP is witnessing persistent strength in the Technology Enabled Products segment, driven by strong momentum in medical products businesses. Growth in demand for electromagnetic tracking solutions across neurological, cardiac and orthopedic precision measurement applications is fostering the growth of the NDI business within the segment.

Solid performance of the Verathon business, supported by strength across single-use BFlex & GlideScope offerings, bodes well for the segment. The company remains optimistic about new product introductions planned for the rest of the year. Also, the growing popularity of its cloud-based software solution is likely to aid the Neptune business. In first-quarter 2026, the segment’s organic revenues increased 7.1% on a year-over-year basis. For the balance of the year, Roper expects the segment’s organic revenues to increase in the mid-single-digit range.

Also, the growing popularity of its products and solutions across the Deltek, Vertafore, PowerPlan and Aderant businesses is driving ROP’s Application Software segment. Apart from this, strong momentum across the ConstructConnect, Subsplash and SoftWriters businesses, augurs well for its Network Software unit. Driven by strength across its businesses, the company expects total revenues to increase approximately 8% in 2026 from the year-ago level. Organic revenues are estimated to rise approximately 5-6% year over year.

Performance Snapshot of ROP’s Peers

Among its major peers, Agilent Technologies, Inc. A has a significant exposure to the healthcare industry, which holds long-term prospects. Agilent’s strength in liquid chromatography systems and components and liquid chromatography mass spectrometry systems remains a plus. The broad-based demand in pharma, diagnostics and applied markets remains a tailwind for Agilent.

Rockwell Automation, Inc. ROK is benefiting from broadening its portfolio of hardware and software products, solutions and services. In Rockwell's Life Science business, the combination of FactoryTalk Pharma Suite MES and FactoryTalk Optix helped secure a competitive win for an active pharma ingredient application. For fiscal 2026, Rockwell raised both its reported and organic sales growth view to 5-9% year over year.

ROP’s Price Performance, Valuation and Estimates

Shares of Roper have gained 5.2% in the past month compared with the industry’s growth of 2.1%.Zacks Investment Research

Image Source: Zacks Investment Research

From a valuation standpoint, ROP is trading at a forward price-to-earnings ratio of 14.58X compared with the industry’s average of 17.57X. Roper carries a Value Score of C.

Story Continues

Zacks Investment Research

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for ROP’s 2025 and 2026 earnings has increased over the past 60 days.Zacks Investment Research

Image Source: Zacks Investment Research

Roper currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Agilent Technologies, Inc. (A) : Free Stock Analysis Report

Roper Technologies, Inc. (ROP) : Free Stock Analysis Report

Rockwell Automation, Inc. (ROK) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Is ROP a good stock to buy? We came across a bullish thesis on Roper Technologies, Inc. on Quality At A Fair Price’s Substack. In this article, we will summarize the bulls’ thesis on ROP. Roper Technologies, Inc.'s share was trading at $333.75 as of June 8th. ROP’s trailing and forward P/E were 20.75 and 15.34 respectively according to Yahoo Finance.Atlassian (TEAM) Introduces AI-Powered Visual Capabilities in Confluence

Copyright: welcomia / 123RF Stock Photo

Roper Technologies (ROP) is emerging as a compelling long-term investment opportunity as the market appears to be undervaluing the company despite its consistent execution, resilient business model, and strong shareholder returns. The company operates a diversified portfolio of vertical software businesses and technology-enabled products that serve highly defensible niche markets across healthcare, industrials, transportation, and enterprise software.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

This asset-light and recurring revenue-driven model has allowed Roper Technologies to compound earnings steadily while maintaining strong free cash flow generation and high margins. Although the stock currently offers a modest dividend yield of roughly 1%, that figure stands significantly above its 5-year average dividend yield of 0.58%, implying that the shares may be undervalued by more than 40% based on Dividend Yield Theory.

This disconnect creates an attractive entry point for investors seeking a high-quality compounder trading below intrinsic value. Roper Technologies further reinforced its shareholder-friendly capital allocation strategy with a 10.3% dividend increase late last year, extending a long track record of dividend growth that has consistently ranged between 10% and 12% annually over the past decade. The company’s ability to sustain double-digit dividend growth reflects confidence in its durable cash flows, pricing power, and acquisition-driven growth strategy.

Looking ahead, Roper Technologies is positioned to benefit from continued demand for mission-critical software solutions and operational technologies, while its projected forward annual return estimate of 16.5% highlights the potential for substantial upside as valuation multiples normalize and earnings continue compounding over time.

Previously, we covered a bullish thesis on Roper Technologies, Inc. (ROP) by D Invests in February 2025, which highlighted the company’s transformation into a high-margin software-focused compounder driven by disciplined acquisitions and recurring revenue growth. ROP's stock price has depreciated by approximately 41.81% since our coverage. Quality At A Fair Price shares a similar view but emphasizes on the company’s undervaluation and dividend growth potential.

Story Continues

Roper Technologies, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 49 hedge fund portfolios held ROP at the end of the first quarter which was 61 in the previous quarter. While we acknowledge the risk and potential of ROP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ROP and that has 10,000% upside potential, check out our report about this cheapest AI stock.

Disclosure: None.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Multiple insiders secured a larger position in Roper Technologies, Inc. (NASDAQ:ROP) shares over the last 12 months. This is reassuring as this suggests that insiders have increased optimism about the company's prospects.

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

The Last 12 Months Of Insider Transactions At Roper Technologies

The President Laurence Hunn made the biggest insider purchase in the last 12 months. That single transaction was for US$903k worth of shares at a price of US$452 each. That means that even when the share price was higher than US$334 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

Over the last year, we can see that insiders have bought 4.60k shares worth US$1.9m. But insiders sold 752.00 shares worth US$406k. In total, Roper Technologies insiders bought more than they sold over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

View our latest analysis for Roper Technologies NasdaqGS:ROP Insider Trading Volume June 11th 2026

Roper Technologies is not the only stock insiders are buying. So take a peek at this freelist of under-the-radar companies with insider buying.

Does Roper Technologies Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Roper Technologies insiders own 0.4% of the company, worth about US$124m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

What Might The Insider Transactions At Roper Technologies Tell Us?

The fact that there have been no Roper Technologies insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. Judging from their transactions, and high insider ownership, Roper Technologies insiders feel good about the company's future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Every company has risks, and we've spotted 1 warning sign for Roper Technologies you should know about.

Story Continues

Of course Roper Technologies may not be the best stock to buy. So you may wish to see this freecollection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

DAT SolutionsConvoyPlatformReloads

PORTLAND, Ore., June 11, 2026 (GLOBE NEWSWIRE) -- DAT Freight & Analytics has expanded the reloads feature in the Convoy Platform app, a trucking app that helps carriers book and haul freight, giving carriers a view of available freight near the delivery stop before they book a load. With earlier visibility into backhaul options, carriers can plan beyond the first leg, factor the full trip into their bidding decision, and avoid costly empty miles.

How Reloads Work In the Convoy Platform app, carriers will see a badge at the top of the load details indicating the number of reloads available in the delivery market.

Full information on the available reloads can be found below the facility information on the load details page. Each reload option shows the book-now rate, deadhead miles to the pickup, and pickup timing after delivery. From there, carriers book or bid directly on that freight in the Convoy app.

Know Before You Go "Carriers want to keep moving, and every load matters. Fuel costs are up, deadheading is a waste, and eliminating empty miles is critical to running a profitable business," said Bill Driegert, EVP, Convoy Platform. "Reloads are a simple way to give carriers better information before booking so they can make better decisions and keep their trucks moving."

ExpedICE Logistics, a refrigerated carrier based in Terre Haute, Indiana, is an early adopter of the expanded reloads feature.

"Knowing what freight is available to us before we go into a market helps us evaluate each opportunity before booking,” said Amber Laughrey of ExpedICE Logistics. “Reloads help us avoid weaker markets, reduce deadhead miles, and keep the truck moving profitably.”

Carriers not on the Convoy Platform yet can download the free trucking app to book and haul broker-verified loads from a trusted free load board: convoy.com/download-app

About DAT Freight & Analytics DAT Freight & Analytics operates the DAT One truckload freight marketplace; Convoy Platform, an automated freight-matching technology; DAT iQ analytics service; Trucker Tools load-visibility platform; and Outgo factoring and financial services for truckers. Shippers, transportation brokers, carriers, news organizations, and industry analysts rely on DAT for market trends and data insights, informed by nearly 700,000 daily load posts and a database exceeding $1 trillion in freight market transactions.

Founded in 1978, DAT is a business unit of Roper Technologies (Nasdaq: ROP), a constituent of the Nasdaq 100, S&P 500, and Fortune 500. Headquartered in Portland, Oregon, DAT continues to set the standard for innovation in the trucking and logistics industry. Visit dat.com for more information.

Story Continues

Media contacts:

Georgia Jablon DAT Freight & Analytics 904-305-6454; georgia.jablon@dat.com

Stephen Petit SiefkesPetit Communications 425-443-8976; petit@siefkespetit.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2d5a3ed8-267c-4174-b9fe-4ae3b69d4122

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Dodge & Cox Fund, an investment management company, released its first-quarter 2026 investor letter for “Dodge and Cox Stock Fund”. A copy of the letter is available to download here. U.S. equities declined broadly in Q1 2026, with the S&P 500 falling 4.3% amid inflation concerns fueled by the conflict in Iran and disruptions in global energy markets. The Russell 1000 Value index rose 2.1%, outperforming the broader indices, and the Russell 1000 Growth Index, which fell 9.78%. Higher oil prices and interest rate shift pressured growth-oriented tech stocks, leading investors to move away from growth stocks. The Fund's Class I shares returned -1.67%, outperforming the S&P 500, while lagging the Russell 1000 Value Index's 2.10% returns. The firm anticipates that market leadership and sector rotations could affect short-term performance while maintaining a long-term investment outlook. In addition, please check the Fund’s top five holdings to know its best picks in 2026.

In its first-quarter 2026 investor letter, Dodge and Cox Stock Fund highlighted Roper Technologies, Inc. (NASDAQ:ROP) as a newly added position. Roper Technologies, Inc. (NASDAQ:ROP) is a technology company that designs and develops vertical software and technology-enabled products. On June 9, 2026, Roper Technologies, Inc. (NASDAQ:ROP) closed at $335.37 per share. One-month return of Roper Technologies, Inc. (NASDAQ:ROP) was 6.05%, and its shares lost 41.12% over the past 52 weeks. Roper Technologies, Inc. (NASDAQ:ROP) has a market capitalization of $33.84 billion.

Dodge and Cox Stock Fund stated the following regarding Roper Technologies, Inc. (NASDAQ:ROP) in its Q1 2026 investor letter:

"AI continued to dominate sentiment, as investors rewarded perceived AI "winners" and penalized perceived "losers" during the quarter, creating significant valuation dislocations. We believe a value-oriented approach is especially important in the current environment. The notable recent volatility has created opportunities in select areas, including the Software industry.

We also initiated a position in Roper Technologies, Inc. (NASDAQ:ROP), a leading software and technology company that provides critical technology solutions and systems of record for small and medium businesses. Following a recent decline in its stock price, Roper now trades at 16.1 times forward earnings—an attractive valuation given the company’s importance to its customer base, strong free cash flow generation, and active share buyback program."

Story Continues

Roper (ROP) Ups Guidance, Announces $3B Buyback Expansion

Roper Technologies, Inc. (NASDAQ:ROP) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 49 hedge fund portfolios held Roper Technologies, Inc. (NASDAQ:ROP) at the end of the first quarter, up from 61 in the previous quarter. While we acknowledge the potential of Roper Technologies, Inc. (NASDAQ:ROP) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Roper Technologies, Inc. (NASDAQ:ROP) and shared the list of most oversold S&P 500 stocks so far in 2026. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Wenn Sie sich fragen, ob Roper Technologies bei einem aktuellen Aktienkurs von etwa US$332 pro Anteil einen guten Wert bietet, ist die Frage, wie der Kurs im Vergleich zu einer fairen Schätzung des Unternehmenswertes steht. Der Aktienkurs ist über längere Zeiträume relativ schwach gewesen, mit einem Rückgang um 23,6% seit Beginn des Jahres und um 41,6% innerhalb der letzten zwölf Monate. Im letzten Woche stieg er um 2,0%, nachdem er im letzten Monat um 3,2% gefallen war. Die jüngste Berichterstattung hat sich auf die Frage konzentriert, wie der langfristige Aktienkursverlauf mit dem Ruf des Unternehmens als Software- und Technologieunternehmen verglichen werden kann. Dies hat frische Diskussionen über die Frage ausgelöst, ob die Erwartungen einfach zu hoch waren oder das Markt zu pessimistisch geworden ist. Diese Art von Diskussion führt oft dazu, dass Investoren prüfen, ob der aktuelle Kurs den Qualitäten und Stabilität des zugrunde liegenden Unternehmens gerecht wird.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investoren, die sich für Computer-IT-Dienstleistungsaktien interessieren, haben wahrscheinlich sowohl Roper Technologies (ROP) als auch Jack Henry (JKHY) kennengelernt. Aber welche dieser beiden Aktien bietet den Investoren derzeit die bessere Wertmöglichkeit? Lassen Sie uns genauer hinschauen.

Es gibt viele Strategien zum Entdecken von Wertaktien, aber wir haben festgestellt, dass das Paaren eines starken Zacks-Rangs mit einem beeindruckenden Wertgrad in unserem Style-Scores-System die besten Renditen produziert. Der bewährte Zacks-Rang betont Unternehmen mit positiven Revisionstrends für ihre Earnings-Schätzungen und unsere Style-Scores hervorheben Aktien mit bestimmten Merkmalen.

Derzeit halten sowohl Roper Technologies als auch Jack Henry einen Zacks-Rang von #2 (Kaufen). Der Zacks-Rang bevorzugt Aktien, die kürzlich positive Revisionen ihrer Earnings-Schätzungen gesehen haben, daher sollten sich Investoren sicher sein, dass beide Unternehmen verbesserte Earnings-Outlooks haben. Wertinvestoren werden jedoch mehr als nur das interessieren.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der Anwendungssoftware-Segment bleibt das Rückgrat der Wachstumsstrategie von Roper Technologies, Inc. und liefert eine konsistente Expansion, die durch gesunde Nachfrage in seinen Aderant, Deltek, Vertafore, PowerPlan und CentralReach-Geschäften unterstützt wird. Die Nachfrage bleibt stark in Schlüsselendmärkten wie privatsächlicher Projektmanagement, höherer Bildung, Versicherungen und Rechtsdienstleistungen.

Der Segment profitiert auch von der zunehmenden Einführung von SaaS-Angeboten und laufender GenAI-Innovation. Aderant gewinnt durch starke Nachfrage nach seinen SaaS-Lösungen, während Deltek weiterhin soliden Tritt in der Privatwirtschaft zeigt. Vertafores Wachstum wird durch starke Umsetzung bei großen Unternehmen getrieben und führt zu robustem jährlich wiederkehrendem Umsatz (ARR)-Wachstum. Inzwischen unterstützt PowerPlan hohe Kundenbindung und wachsende Aufnahme neuer SaaS-Produkte, während CentralReach weiterhin starke wiederkehrende Umsatzerwirtschaftung erzielt.

Im ersten Quartal 2026 machte der Anwendungssoftware-Segment fast 57% des Gesamtumsatzes von Roper aus. Der Segmentumsatz stieg um 11,5% im Vergleich zum Vorjahr auf 1,19 Milliarden US-Dollar. Diese Leistung unterstreicht die zunehmende Größe und strategische Bedeutung des Segments innerhalb der Unternehmensportfolio.

Zukünftig erwartet Roper, dass das Segment soliden Impuls durch Erreichen von mehr als mittlerer Doppelstelligkeit im Rest 2026 beibehalten wird, unterstützt durch seine Abonnement-basierten Umsatzeinahmen, wachsende Softwareanwendungen und fortlaufende Produktverbesserungen. Diese Faktoren positionieren den Anwendungssoftware-Segment als wichtigen Beitrag zum langfristigen Wachstum und der Rentabilität von Roper.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Wir sprechen über die beliebte Roper Technologies, Inc. (NASDAQ:ROP). Die Aktien der Firma erhielten in den letzten Monaten viel Aufmerksamkeit durch einen starken Preisverlauf auf dem NASDAQGS, der bis zu US$368 anstieg und dann bis zu US$316 fiel. Einige Preisschwankungen können Investoren eine bessere Gelegenheit bieten, in die Aktie einzusteigen und möglicherweise bei einem niedrigeren Preis zu kaufen. Eine Frage ist, ob der aktuelle Handelspreis von US$344 des großen Kapitalgegenstands Roper Technologies den tatsächlichen Wert widerspiegelt oder ob er unterbewertet ist und uns die Gelegenheit bietet, zu kaufen? Lassen Sie uns einen Blick auf das Ausblick und den Wert von Roper Technologies auf der Grundlage der neuesten Finanzdaten werfen, um zu sehen, ob es Catalysts für einen Preiswechsel gibt.